{"id":22517,"date":"2022-11-25T11:00:28","date_gmt":"2022-11-25T10:00:28","guid":{"rendered":"https:\/\/idibell.cat\/?p=22517"},"modified":"2022-11-23T16:19:03","modified_gmt":"2022-11-23T15:19:03","slug":"el-grup-de-cancer-de-prostata-obte-una-subvencio-dels-fons-federals-del-departament-de-defensa-dels-eua","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/11\/el-grup-de-cancer-de-prostata-obte-una-subvencio-dels-fons-federals-del-departament-de-defensa-dels-eua\/","title":{"rendered":"El Grup de C\u00e0ncer de Pr\u00f2stata obt\u00e9 una subvenci\u00f3 dels fons federals del Departament de Defensa dels EUA"},"content":{"rendered":"<p>El grup <em>Mecanismes de Resist\u00e8ncia i Progressi\u00f3 en C\u00e0ncer de Pr\u00f2stata<\/em> del Programa de Mecanismes Moleculars i Ter\u00e0pia Experimental en Oncologia (Oncobell) de l&#8217;IDIBELL i l&#8217;Institut Catal\u00e0 d&#8217;Oncologia (ICO) liderat pel Dr. \u00c0lvaro Ayt\u00e9s ha rebut 800.000 d\u00f2lars a l&#8217;Idea Award-Prostate Cancer Research Program (PCRP-IDA) convocat\u00f2ria del Departament de Defensa dels EUA. La subvenci\u00f3 ajudar\u00e0 a finan\u00e7ar un projecte de 3 anys coordinat pel Dr. Ayt\u00e9s en col\u00b7laboraci\u00f3 amb la Dra. Himisha Beltran al Dana Farber Cancer Institute (Boston, EUA). Aquesta ajuda est\u00e0 en l\u00ednia i \u00e9s un seguiment natural del projecte del Dr. Ayt\u00e9s finan\u00e7at pr\u00e8viament sota el FY17 PCRP\u2010IDA del Departament de Defensa dels EUA, en qu\u00e8 els investigadors van analitzar els mecanismes de resist\u00e8ncia a la ter\u00e0pia del c\u00e0ncer de pr\u00f2stata.<\/p>\n<p>El nou estudi proposat abordar\u00e0 com la desregulaci\u00f3 dels remodeladors de la cromatina al c\u00e0ncer de pr\u00f2stata resistent a la ter\u00e0pia incideix en el microambient immunitari del tumor. A m\u00e9s, proporcionar\u00e0 informaci\u00f3 sobre enfocaments nous per tractar els tumors de pr\u00f2stata metast\u00e0sics que actualment s\u00f3n resistents a la immunoter\u00e0pia. Els investigadors explotaran sofisticats models de c\u00e0ncer de pr\u00f2stata en ratolins modificats gen\u00e8ticament, perfils gen\u00f2mics avan\u00e7ats i enfocaments de biologia computacional per identificar i validar nous mecanismes al c\u00e0ncer de pr\u00f2stata letal. Investigaran com es poden explotar aquests mecanismes com a vulnerabilitats del c\u00e0ncer i objectius farmacol\u00f2gics potencials utilitzant eines d&#8217;edici\u00f3 gen\u00e8tica i els provaran en assajos precl\u00ednic<\/p>\n<p>&nbsp;<\/p>\n<p><strong><em>T\u00edtol del projecte: Dissecting the role of cancer cell chromatin remodeling on the landscape of tumor immune microenvironment.<\/em><\/strong><\/p>\n<p><strong><em>PI:<\/em><\/strong><em> El Dr. \u00c1lvaro Ayt\u00e9s es Jefe de Grupo del Laboratorio de Resistencia y mecanismos de progresi\u00f3n en C\u00e1ncer de Pr\u00f3stata en el programa de Investigaci\u00f3n en Oncolog\u00eda (OncoBELL) y el Programa Contra la Resistencia Terap\u00e9utica del C\u00e1ncer (ProCURE) del Instituto Catal\u00e1n de Oncolog\u00eda (ICO) en el IDIBELL.<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;ajuda del Departament de Defensa dels EUA finan\u00e7ar\u00e0 un projecte de 3 anys per estudiar el paper de la cromatina de les c\u00e8l\u00b7lules canceroses al microambient immunitari del tumor de pr\u00f2stata.<\/p>\n","protected":false},"author":8,"featured_media":22518,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,395,447,452],"tags":[],"class_list":["post-22517","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-mecanismes-de-resistencia-i-progressio-en-el-cancer-de-prostata","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-procure"],"publishpress_future_action":{"enabled":false,"date":"2024-11-12 12:19:40","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22517"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=22517"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22517\/revisions"}],"predecessor-version":[{"id":22519,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22517\/revisions\/22519"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/22518"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=22517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=22517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=22517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}